Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CanSino Partners with Ocugen to Develop Gene Therapy Eye Treatment

publication date: Sep 30, 2019

CanSino Biologics of Tianjin acquired China rights to a portfolio of inherited retinal disease treatments being developed by Ocugen (NSDQ: OCGN) of Massachusetts. CanSino will also partner with Ocugen to provide CMC development and clinical supplies of OCU400, Ocugen’s lead gene therapy candidate. Ocugen's portfolio of novel clinical stage drugs are intended to treat rare eye diseases. In addition, CanSino will have an option to manufacture the candidates for Ocugen. An innovative vaccine company, CanSino has a viral vector program. No financial details were disclosed. More details....

Stock Symbol: (HK: 6185)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.